GLP1 agonists like OZMP can lead to reduced food intake, decreased consumption in other areas such as drinking, shopping, and smoking. This poses a challenge in a consumer economy that depends on people's consumption.
The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too.
This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggleston, engineered by Rob Byers, and hosted by Noel King.
Transcript at vox.com/todayexplained
Support Today, Explained by making a financial contribution to Vox! bit.ly/givepodcasts
Learn more about your ad choices. Visit podcastchoices.com/adchoices